AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7664435 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol 100 mg BID
Number of subjects: 233
Study 7664435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 2665687 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 57
Study 2665687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 57
Study 2665687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 360238 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31142156 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy (HT) with conjugated estrogens/medroxyprogesterone acetate (0.30 mg/1.5 mg/d)
Number of subjects: 75
Study 31142156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (weekly for 3 months)
Number of subjects: 75
Study 31142156 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoestrogens (soy isoflavones 75 mg/2/d for 3 months)
Number of subjects: 75
Study 29390421 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib-based chemotherapy
Number of subjects: 240
Study 29390421 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 240
Study 29390421 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib-based chemotherapy (in patients with positive COX-2)
Number of subjects: 240
Study 24911964 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg lycopene daily for 2 months
Number of subjects: 72
Study 24911964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 23221015 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk-like textile for bedding paired with high-absorbency adult incontinence briefs
Number of subjects: 46
Study 23221015 — intervention group
Group type: COMPARATOR
Intervention: Usual care with plain-weave cotton/polyester bed sheets and adult incontinence briefs
Number of subjects: 46
Study 20347837 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weekly classes of yoga
Number of subjects: 262
Study 20347837 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 262
Study 18981306 — intervention group
Group type: EXPERIMENTAL
Intervention: ONBEAT (on-pump beating heart CABG)
Number of subjects: 50
Study 18981306 — intervention group
Group type: COMPARATOR
Intervention: ONSTOP (conventional on-pump CABG)
Number of subjects: 50
Study 16477954 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (intravenous injections of 0.1 mg/kg)
Number of subjects: 7
Study 16477954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous injections of 0.9% NaCl)
Number of subjects: 7
Study 16477954 — intervention group
Group type: COMPARATOR
Intervention: Untreated (baseline)
Number of subjects: 7
Study 12785319 — intervention group
Group type: COMPARATOR
Intervention: 200 gram tension on extraocular muscle (EOM)
Number of subjects: 842
Study 12785319 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 gram tension on one muscle
Number of subjects: 842
Study 12785319 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 gram tension on another muscle
Number of subjects: 842
Study 12785319 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting 3 minutes after profound initial OCR
Number of subjects: 842
Study 10500826 — intervention group
Group type: EXPERIMENTAL
Intervention: High anthracycline dose intensity (H/A)
Number of subjects: 76
Study 10500826 — intervention group
Group type: COMPARATOR
Intervention: Low anthracycline dose intensity (L/A)
Number of subjects: 76
Study 10500826 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic marrow transplant (allo‐BMT)
Number of subjects: 76
Study 10500826 — intervention group
Group type: COMPARATOR
Intervention: Favorable prognostic factors (FPF) 0-1
Number of subjects: 76
Study 10500826 — intervention group
Group type: COMPARATOR
Intervention: Favorable prognostic factors (FPF) 2-3
Number of subjects: 76
Study 10500826 — intervention group
Group type: COMPARATOR
Intervention: Favorable prognostic factors (FPF) 4
Number of subjects: 76
Study 10500826 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 50 years
Number of subjects: 76
Study 7797827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 250 mg
Number of subjects: 59
Study 7797827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2403448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 to 20 mg by mouth twice a day
Number of subjects: 12
Study 2403448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg by mouth four times a day
Number of subjects: 12
Study 2403448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor tissue assay for estrogen and progesterone receptors
Number of subjects: 12
Study 343739 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hemodilution (mean hematocrit 27%)
Number of subjects: 29
Study 343739 — intervention group
Group type: COMPARATOR
Intervention: Extreme hemodilution (mean hematocrit 18%)
Number of subjects: 29
Study 31276840 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's voice alarm
Number of subjects: 176
Study 31276840 — intervention group
Group type: EXPERIMENTAL
Intervention: Female stranger's voice alarm
Number of subjects: 176
Study 31276840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency 500 Hz square wave tone alarm
Number of subjects: 176
Study 31276840 — intervention group
Group type: COMPARATOR
Intervention: Conventional residential high-frequency tone alarm
Number of subjects: 176
Study 30921595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 104
Study 30921595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 104
Study 27590412 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM through two leads (Group A)
Number of subjects: 48
Study 27590412 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM through one lead (Group B)
Number of subjects: 48
Study 23570538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient hybrid closed-loop therapy (HCLC)
Number of subjects: 48
Study 23570538 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient sensor‐augmented pump (SAP) therapy
Number of subjects: 48
Study 21838198 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 20
Study 21838198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19776092 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate/minocycline
Number of subjects: 44
Study 19776092 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate/placebo
Number of subjects: 44
Study 16507199 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 19
Study 16507199 — intervention group
Group type: COMPARATOR
Intervention: Liver surgery (control group)
Number of subjects: 19
Study 15636296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation with change of ventilator circuits every 48 hours
Number of subjects: 304
Study 15636296 — intervention group
Group type: COMPARATOR
Intervention: Ventilation with no change of circuits
Number of subjects: 304
Study 11374283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n = 12): Donor cornea fixed in the same position as the recipient
Number of subjects: 38
Study 11374283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n = 12): Donor corneas transplanted with the axis in opposition to the axis of the recipient
Number of subjects: 38
Study 11374283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (n = 14): Donor corneas transplanted in the same orientation as the recipient
Number of subjects: 38
Study 11374283 — intervention group
Group type: COMPARATOR
Intervention: Group D (n = 40): Control group
Number of subjects: 38
Study 9232210 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPT (1 g p.o. T.I.D.)
Number of subjects: 10
Study 9232210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8388356 — intervention group
Group type: EXPERIMENTAL
Intervention: Venography
Number of subjects: 0
Study 8388356 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized venographic technique
Number of subjects: 0
Study 3434164 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4.5 micrograms kg‐1)
Number of subjects: 21
Study 3434164 — intervention group
Group type: COMPARATOR
Intervention: Standardized general anaesthesia (Control)
Number of subjects: 21
Study 28177489 — intervention group
Group type: EXPERIMENTAL
Intervention: mTHS (Tobacco Heating System 2.2)
Number of subjects: 160
Study 28177489 — intervention group
Group type: COMPARATOR
Intervention: mCC (menthol conventional cigarettes)
Number of subjects: 160
Study 28177489 — intervention group
Group type: COMPARATOR
Intervention: SA (smoking abstinence)
Number of subjects: 160
Study 26940165 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone (0.625 mg/day)
Number of subjects: 4347
Study 26940165 — intervention group
Group type: COMPARATOR
Intervention: Estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 4347
Study 25465830 — intervention group
Group type: EXPERIMENTAL
Intervention: CCU admission
Number of subjects: 5094
Study 25465830 — intervention group
Group type: COMPARATOR
Intervention: Ward admission
Number of subjects: 5094
Study 25465830 — intervention group
Group type: COMPARATOR
Intervention: Regional comparison (AP, CE, LA, WE) vs NA CCU patients
Number of subjects: 5094
Study 22483183 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture
Number of subjects: 16
Study 22483183 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 16
Study 19910076 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT/CDDP (cisplatin 75 mg/m² plus docetaxel 75 mg/m² on day 1 every week)
Number of subjects: 76
Study 19910076 — intervention group
Group type: COMPARATOR
Intervention: VNR/CDDP (cisplatin 80 mg/m² on day 1 plus vinorelbine 30 mg/m² on day 1 and 8 every 3 weeks)
Number of subjects: 76
Study 19910076 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT/CDDP
Number of subjects: 76
Study 19910076 — intervention group
Group type: COMPARATOR
Intervention: VNR/CDDP
Number of subjects: 76
Study 18403492 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide for 5 days in 28-day cycles, daily thalidomide, and celecoxib
Number of subjects: 50
Study 16007352 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal island flap anoplasty (IFA)
Number of subjects: 79
Study 16007352 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CVN)
Number of subjects: 79
Study 12963897 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus adapalene
Number of subjects: 249
Study 12963897 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus vehicle
Number of subjects: 249
Study 11022366 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site presentations led by a cardiologist and a quality improvement specialist
Number of subjects: 1367
Study 11022366 — intervention group
Group type: COMPARATOR
Intervention: Mailed feedback
Number of subjects: 1367
Study 8799513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200 mg
Number of subjects: 15
Study 8799513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg
Number of subjects: 15
Study 8799513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1386063 — intervention group
Group type: EXPERIMENTAL
Intervention: Betagen, 20 micrograms
Number of subjects: 220
Study 1386063 — intervention group
Group type: COMPARATOR
Intervention: Lanzhou, 20 micrograms
Number of subjects: 220
Study 1386063 — intervention group
Group type: EXPERIMENTAL
Intervention: Betagen, 20 micrograms + HBIG
Number of subjects: 220
Study 1386063 — intervention group
Group type: EXPERIMENTAL
Intervention: Betagen, 10 micrograms + HBIG
Number of subjects: 220
Study 1386063 — intervention group
Group type: EXPERIMENTAL
Intervention: Betagen alone
Number of subjects: 220
Study 1386063 — intervention group
Group type: COMPARATOR
Intervention: Lanzhou
Number of subjects: 220
Study 6480923 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium sulfide lotion
Number of subjects: 20
Study 6480923 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 20
Study 30621711 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen treatment in experimental group
Number of subjects: 30
Study 30621711 — intervention group
Group type: COMPARATOR
Intervention: Normal saline treatment in blank and model groups
Number of subjects: 30
Study 30621711 — intervention group
Group type: COMPARATOR
Intervention: Experimental group vs. Model group
Number of subjects: 30
Study 30159944 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-side intervention providing in-kind transfers to users of three services
Number of subjects: 0
Study 30159944 — intervention group
Group type: COMPARATOR
Intervention: Cooperative performance payments to community health worker cooperatives
Number of subjects: 0
Study 27193737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐based cancer recovery (MBCR)
Number of subjects: 252
Study 27193737 — intervention group
Group type: COMPARATOR
Intervention: Supportive expressive group therapy (SET)
Number of subjects: 252
Study 23924046 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Enhanced HNC (TE-HNC)
Number of subjects: 15
Study 23924046 — intervention group
Group type: COMPARATOR
Intervention: Standard HNC
Number of subjects: 15
Study 22682024 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor long-lasting insecticidal nets (200 mg/m² alpha-cypermethrin)
Number of subjects: 936
Study 22682024 — intervention group
Group type: COMPARATOR
Intervention: Untreated polyester net (100 denier)
Number of subjects: 936
Study 22682024 — intervention group
Group type: COMPARATOR
Intervention: No net
Number of subjects: 936
Study 22682024 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor long-lasting insecticidal nets
Number of subjects: 936
Study 19531246 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Tomato intervention to support maintenance of fruit intake in Year 3 children.
Number of subjects: 54
Study 19531246 — intervention group
Group type: COMPARATOR
Intervention: 5 A DAY booklet (control group).
Number of subjects: 54
Study 17698804 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential chemotherapy with PBSC support (two cycles of cyclophosphamide and paclitaxel followed by three cycles of HD carboplatin and paclitaxel with PBSC support, HD melphalan added to the final cycle)
Number of subjects: 149
Study 17698804 — intervention group
Group type: COMPARATOR
Intervention: Standard combination chemotherapy
Number of subjects: 149
Study 17698804 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sequential chemotherapy with PBSC support
Number of subjects: 149
Study 15155714 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exhaustive cycling exercise
Number of subjects: 8
Study 11476777 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG IUS)
Number of subjects: 60
Study 11476777 — intervention group
Group type: COMPARATOR
Intervention: Endometrial resection
Number of subjects: 60
Study 9620526 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine 15 microg + isoproterenol 1.5 microg
Number of subjects: 75
Study 9620526 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine 7.5 microg + isoproterenol 3 microg
Number of subjects: 75
Study 9620526 — intervention group
Group type: EXPERIMENTAL
Intervention: isoproterenol 3 microg
Number of subjects: 75
Study 9620526 — intervention group
Group type: EXPERIMENTAL
Intervention: epinephrine 15 microg
Number of subjects: 75
Study 9620526 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 75
Study 7799108 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (nicardipine)
Number of subjects: 0
Study 7799108 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (trichlormethiazide)
Number of subjects: 0
Study 7799108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3260167 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexin Continus
Number of subjects: 12
Study 3260167 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocid R
Number of subjects: 12
Study 3260167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30191883 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiotherapy
Number of subjects: 0
Study 30191883 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage Radiotherapy
Number of subjects: 0
Study 26580093 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational vaccine (Shan5™)
Number of subjects: 1100
Study 25713659 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic-walking training for 8 weeks
Number of subjects: 24
Study 23549123 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml ropivacaine 7.5 mg/ml
Number of subjects: 50
Study 23549123 — intervention group
Group type: COMPARATOR
Intervention: 30 ml 0.9% saline
Number of subjects: 50
Study 19734132 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 218
Study 19734132 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 180 mg
Number of subjects: 218
Study 19734132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 17570651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10mg with low-calorie diet
Number of subjects: 60
Study 17570651 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day with low-calorie diet
Number of subjects: 60
Study 17570651 — intervention group
Group type: COMPARATOR
Intervention: Low-calorie diet only
Number of subjects: 60
Study 15970733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 127
Study 15970733 — intervention group
Group type: COMPARATOR
Intervention: Normobaric oxygen
Number of subjects: 127
Study 15970733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive sequelae and suicide attempt
Number of subjects: 127
Study 15970733 — intervention group
Group type: COMPARATOR
Intervention: No cognitive sequelae or suicide attempt
Number of subjects: 127
Study 12698218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol condition
Number of subjects: 0
Study 12698218 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study 10319358 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triacylglycerol (STG) emulsion
Number of subjects: 40
Study 10319358 — intervention group
Group type: COMPARATOR
Intervention: Physical mixture of long‐chain triacylglycerols/medium‐chain triacylglycerols (LCT/MCT) emulsion
Number of subjects: 40
Study 8733039 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg once daily
Number of subjects: 23
Study 8733039 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5 mg 12-hourly
Number of subjects: 23
Study 8733039 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg once daily
Number of subjects: 23
Study 8733039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1937072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (5 micrograms)
Number of subjects: 0
Study 1937072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (10 micrograms)
Number of subjects: 0
Study 1937072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (50 micrograms)
Number of subjects: 0
Study 1937072 — intervention group
Group type: EXPERIMENTAL
Intervention: BW245C (2.5 micrograms)
Number of subjects: 0
Study 7146854 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized notice
Number of subjects: 222
Study 7146854 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer's notice
Number of subjects: 222
Study 30985556 — intervention group
Group type: EXPERIMENTAL
Intervention: DOR/3TC/TDF
Number of subjects: 670
Study 30985556 — intervention group
Group type: COMPARATOR
Intervention: Baseline Regimen
Number of subjects: 670
Study 28710205 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary protocol
Number of subjects: 439
Study 28710205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention + healthy food supplement (30 g walnuts/day)
Number of subjects: 439
Study 28710205 — intervention group
Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 439
Study 26050853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tualang honey + antibiotic
Number of subjects: 63
Study 26050853 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic only
Number of subjects: 63
Study 23429699 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol, ramipril (or candesartan if ramipril was not tolerated), spironolactone, and furosemide
Number of subjects: 66
Study 21209031 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogenic oral contraceptive
Number of subjects: 34
Study 21209031 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 34
Study 21209031 — intervention group
Group type: COMPARATOR
Intervention: Control (women without hyperandrogenism)
Number of subjects: 34
Study 19805783 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic science group
Number of subjects: 96
Study 19805783 — intervention group
Group type: COMPARATOR
Intervention: Structured algorithm group
Number of subjects: 96
Study 19805783 — intervention group
Group type: COMPARATOR
Intervention: Feature list group
Number of subjects: 96
Study 19805783 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 96
Study 16405274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal xylometazoline (XYLO) 0.1% (1 spray each nostril)
Number of subjects: 36
Study 16405274 — intervention group
Group type: COMPARATOR
Intervention: Nasal mometasone furoate (MF) 200 mcg daily
Number of subjects: 36
Study 12601116 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD3-stimulated CD8+ T cells from patients with SPMS
Number of subjects: 0
Study 12601116 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 10500311 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (20 mg IV bolus followed by 60 mg infusion over 1 hour)
Number of subjects: 13
Study 10500311 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus (80 mg)
Number of subjects: 13
Study 10500311 — intervention group
Group type: EXPERIMENTAL
Intervention: Split bolus (2 x 40 mg at 30-minute intervals)
Number of subjects: 13